LSTA-201 is under clinical development by Lisata Therapeutics and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase I drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LSTA-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CLBS-201 is under development for the treatment of chronic kidney disease, type 2 diabetes and diabetic nephropathy. The drug candidate consists of CD34+ cells that are mobilized by granulocyte colony-stimulating factor (G-CSF). It is administered through intraarterial route.
Lisata Therapeutics overview
Lisata Therapeutics, formerly Caladrius Biosciences Inc, is a biopharmaceutical company. It discovers and develops cellular therapies for the treatment of cardiovascular indications and autoimmune diseases. It is investigating XOWNA for the treatment of coronary microvascular dysfunction; HONEDRA against critical limb ischemia and buerger’s disease. The company is also evaluating CLBS201 for the treatment of diabetic kidney disease (DKD); and CLBS14 to treat no-option refractory disabling angina. Lisata Therapeutics utilizes its proprietary CD34+ cell therapy technology to develop therapies for ischemia diseases. It serves biotechnology, pharmaceutical and medical product companies, and academic research institutions. Lisata Therapeutics is headquartered in Basking Ridge, New Jersey, the US.
For a complete picture of LSTA-201’s drug-specific PTSR and LoA scores, buy the report here.